Evidence map›Paper›PMID 25739834›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2015

Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor.

D Haeusler, L Grassinger, F Fuchshuber, W J Hörleinsberger, R Höftberger, I Leisser, F Girschele, K Shanab, H Spreitzer, W Gerdenitsch and 3 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Adenosine receptors in breast cancer.Molecular biology reports · 2024
    Review
  2. Species dependence of APurinergic signalling · 2023
    Review
  3. Article
  4. Adenosine AJournal of neuroinflammation · 2020
    Article
  5. Article
  6. AMedicinal research reviews · 2018
    Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

D HaeuslerDepartment of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Waehringer Guertel 18-20/3L, 1090, Vienna, Austria.
L Grassinger
F Fuchshuber
W J Hörleinsberger
R Höftberger
I Leisser
F Girschele
K Shanab
H Spreitzer
W Gerdenitsch
M Hacker
W Wadsak
Markus Mitterhauser
Medical University of Vienna · ATUniversity of Vienna · ATFachhochschule Wiener Neustadt · AT

Funding

Austrian Science Fund FWF P 26502
6 · The paper itself

Abstract

purposeSince the adenosine A3 receptor (A3R) is considered to be of high clinical importance in the diagnosis and treatment of ischaemic conditions (heart and brain), glaucoma, asthma, arthritis, cancer and inflammation, a suitable and selective A3R PET tracer such as [(18)F]FE@SUPPY would be of high clinical value for clinicians as well as patients. A3R was discovered in the late 1990s, but there is still little known regarding its distribution in the CNS and periphery. Hence, in autoradiographic experiments the distribution of A3R in human brain and rat tissues was investigated and the specific binding of the A3R antagonist FE@SUPPY and MRS1523 compared. Immunohistochemical staining (IHC) experiments were also performed to validate the autoradiographic findings.

methodsFor autoradiographic competition experiments human post-mortem brain and rat tissues were incubated with [(125)I]AB-MECA and highly selective compounds to block the other adenosine receptor subtypes. Additionally, IHC was performed with an A3 antibody.

resultsSpecific A3R binding of MRS1523 and FE@SUPPY was found in all rat peripheral tissues examined with the highest amounts in the spleen (44.0% and 46.4%), lung (44.5% and 45.0%), heart (39.9% and 42.9%) and testes (27.4% and 29.5%, respectively). Low amounts of A3R were found in rat brain tissues (5.9% and 5.6%, respectively) and human brain tissues (thalamus 8.0% and 9.1%, putamen 7.8% and 8.2%, cerebellum 6.0% and 7.8%, hippocampus 5.7% and 5.6%, caudate nucleus 4.9% and 6.4%, cortex 4.9% and 6.3%, respectively). The outcome of the A3 antibody staining experiments complemented the results of the autoradiographic experiments.

conclusionThe presence of A3R protein was verified in central and peripheral tissues by autoradiography and IHC. The specificity and selectivity of FE@SUPPY was confirmed by direct comparison with MRS1523, providing further evidence that [(18)F]FE@SUPPY may be a suitable A3 PET tracer for use in humans.

Indexed as

Adenosine A3 Receptor AntagonistsAnimalsBrainHumansNicotinic AcidsProtein BindingPyridinesRadiographyRatsReceptor, Adenosine A3Tissue Distribution2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate5-(2-fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylateAdenosine A3 Receptor AntagonistsNicotinic AcidsPyridinesReceptor, Adenosine A3

Identifiers

PMID25739834
PMCPMC4382535
OpenAlexW2005506067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.